Allergic Conjunctivitis Pipeline Insight Report 2023 (Updated)
DelveInsight’s, “Allergic Conjunctivitis Pipeline Insight, 2023,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Allergic Conjunctivitis pipeline landscape. It covers the Allergic Conjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Allergic Conjunctivitis Pipeline Report
- DelveInsight’s Allergic Conjunctivitis pipeline report depicts a robust space with 22+ active players working to develop 22+ pipeline therapies for Allergic Conjunctivitis treatment.
- The leading companies working in the Allergic Conjunctivitis market include Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd., IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, and others.
- Promising Allergic Conjunctivitis Pipeline Therapies in the various stages of development include MDI-1228_mesylate Ophthalmic Solution, MATA trees or MATA grass, and others.
- On August 2023, Shanghai Medinno Pharmaceutical Technology Co., Ltd. announced a study of Phase 1 Clinical Trials for MDI-1228_mesylate Ophthalmic Solution. The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in patients with allergic conjunctivitis and healthy adult participants. This trial also aims to study the preliminary efficacy of MDI-1228_mesylate Ophthalmic Solution in patients with allergic conjunctivitis.
Request a sample and discover the recent advances in Allergic Conjunctivitis Treatment Drugs @ Allergic Conjunctivitis Pipeline Report
The Allergic Conjunctivitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Allergic Conjunctivitis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Allergic Conjunctivitis clinical trial landscape.
Allergic Conjunctivitis Overview
Allergic conjunctivitis is a common, under-appreciated, and largely benign process. It is rarely vision-threatening but can significantly decrease the quality of life for patients. There are three subtypes of simple allergic conjunctivitis: acute, seasonal, and perennial.
Find out more about Allergic Conjunctivitis Treatment Drugs @ Drugs for Allergic Conjunctivitis Treatment
Allergic Conjunctivitis Emerging Drugs Profile
- Reproxalap: Aldeyra Therapeutics
- VSJ-110: Vanda Pharmaceuticals
Allergic Conjunctivitis Pipeline Therapeutics Assessment
There are approx. 22+ key companies which are developing the therapies for Allergic Conjunctivitis. The Allergic Conjunctivitis companies which have their Allergic Conjunctivitis drug candidates in the most advanced stage, i.e. phase III include, Aldeyra Therapeutics.
Learn more about the emerging Allergic Conjunctivitis Pipeline Therapies @ Allergic Conjunctivitis Clinical Trials Assessment
Scope of the Allergic Conjunctivitis Pipeline Report
- Coverage- Global
- Allergic Conjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Allergic Conjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Allergic Conjunctivitis Companies- Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd., IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, and others.
- Allergic Conjunctivitis Pipeline Therapies- MDI-1228_mesylate Ophthalmic Solution, MATA trees or MATA grass, and others.
Dive deep into rich insights for new drugs for Allergic Conjunctivitis Treatment, Visit @ Allergic Conjunctivitis Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Allergic Conjunctivitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Allergic Conjunctivitis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Reproxalap: Aldeyra Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- VSJ-110: Vanda Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- IC 270: IACTA Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Allergic Conjunctivitis Key Companies
- Allergic Conjunctivitis Key Products
- Allergic Conjunctivitis- Unmet Needs
- Allergic Conjunctivitis- Market Drivers and Barriers
- Allergic Conjunctivitis- Future Perspectives and Conclusion
- Allergic Conjunctivitis Analyst Views
- Allergic Conjunctivitis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting
){kind=link}